{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:30:41Z","timestamp":1793896241595,"version":"4.8.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T00:00:00Z","timestamp":1625356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.nucmedbio.2021.06.006","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T12:03:40Z","timestamp":1625141020000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours"],"prefix":"10.1016","volume":"102-103","author":[{"given":"Lorain","family":"Geenen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Nonnekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Konijnenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Baatout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"De Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.nucmedbio.2021.06.006_bb0005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00428-007-0443-2","article-title":"Peptide receptor expression in GEP-NET","volume":"vol. 451","author":"Reubi","year":"2007","journal-title":"Virchows Arch"},{"issue":"5","key":"10.1016\/j.nucmedbio.2021.06.006_bb0010","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1667\/RR3105","article-title":"Renal toxicity after radionuclide therapy","volume":"161","author":"Lambert","year":"2004","journal-title":"Radiat Res"},{"issue":"7","key":"10.1016\/j.nucmedbio.2021.06.006_bb0015","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2967\/jnumed.110.075101","article-title":"Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention","volume":"51","author":"Vegt","year":"2010","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.nucmedbio.2021.06.006_bb0020","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.nucmedbio.2021.06.006_bb0025","first-page":"36","article-title":"Prevalence of gastroenteropancreatic and lung neuroendocrine tumours in the European Union","volume":"27","author":"Bergamasco","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.nucmedbio.2021.06.006_bb0030","first-page":"1","article-title":"New and emerging systemic therapy options for well-differentiated gastroenteropancreatic neuroendocrine tumors","author":"Scoville","year":"2019","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"10.1016\/j.nucmedbio.2021.06.006_bb0035","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177 Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.nucmedbio.2021.06.006_bb0040","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1200\/JCO.2018.78.5865","article-title":"Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-dotatate in the phase III netter-1 trial","volume":"36","author":"Strosberg","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.nucmedbio.2021.06.006_bb0045","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(20)30323-5","article-title":"Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy","volume":"21","author":"Bodei","year":"2020","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.nucmedbio.2021.06.006_bb0050","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1530\/ERC-19-0186","article-title":"The next generation of peptide receptor radionuclide therapy","volume":"26","author":"Brabander","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.nucmedbio.2021.06.006_bb0055","series-title":"Assessment report Lutathera","author":"European Medicines Agency","year":"2018"},{"issue":"3","key":"10.1016\/j.nucmedbio.2021.06.006_bb0060","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11307-014-0795-3","article-title":"SUV of [68Ga]DOTATOC-PET\/CT predicts response probability of PRRT in neuroendocrine tumors","volume":"17","author":"Kratochwil","year":"2015","journal-title":"Mol Imaging Biol"},{"issue":"10","key":"10.1016\/j.nucmedbio.2021.06.006_bb0065","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s00259-016-3382-9","article-title":"Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate","volume":"43","author":"Bergsma","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.nucmedbio.2021.06.006_bb0070","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00259-015-3001-1","article-title":"Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment","volume":"42","author":"Svensson","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2021.06.006_bb0075","series-title":"Summary of product characteristics Lutathera","author":"European Medicines Agency","year":"2017"},{"key":"10.1016\/j.nucmedbio.2021.06.006_bb0080","doi-asserted-by":"crossref","first-page":"5629","DOI":"10.2147\/CMAR.S174907","article-title":"Prognosis of patients with neuroendocrine tumor: a SEER database analysis","volume":"10","author":"Man","year":"2018","journal-title":"Cancer Manag Res"},{"issue":"5","key":"10.1016\/j.nucmedbio.2021.06.006_bb0085","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","volume":"40","author":"Zaknun","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.nucmedbio.2021.06.006_bb0090","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s00259-018-3945-z","article-title":"Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity","volume":"45","author":"Garske-Rom\u00e1n","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.nucmedbio.2021.06.006_bb0095","first-page":"140","article-title":"Practical management of toxicities associated with targeted therapies for advanced gastroenteropancreatic neuroendocrine tumors","volume":"31","author":"Cuyle","year":"2018","journal-title":"Ann Gastroenterol"},{"issue":"5","key":"10.1016\/j.nucmedbio.2021.06.006_bb0100","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1053\/j.semnuclmed.2016.04.006","article-title":"Renal function assessment during peptide receptor radionuclide therapy","volume":"46","author":"Erbas","year":"2016","journal-title":"Semin Nucl Med"},{"issue":"11","key":"10.1016\/j.nucmedbio.2021.06.006_bb0105","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1007\/s00259-007-0457-7","article-title":"Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney","volume":"34","author":"Rolleman","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.nucmedbio.2021.06.006_bb0110","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00259-010-1685-9","article-title":"Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice","volume":"38","author":"Vegt","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.nucmedbio.2021.06.006_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0034019","article-title":"Plga nanoparticles for peptide receptor radionuclide therapy of neuroendocrine tumors: a novel approach towards reduction of renal radiation dose","volume":"7","author":"Arora","year":"2012","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.nucmedbio.2021.06.006_bb0120","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1055\/s-0032-1314859","article-title":"Differential expression of somatostatin receptor subtype 1-5 proteins in numerous human normal tissues","volume":"120","author":"Unger","year":"2012","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"8","key":"10.1016\/j.nucmedbio.2021.06.006_bb0125","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1369\/jhc.2008.950998","article-title":"Expression of somatostatin and somatostatin receptor subtypes 1-5 in human normal and diseased kidney","volume":"56","author":"Bhandari","year":"2008","journal-title":"J Histochem Cytochem"},{"issue":"12","key":"10.1016\/j.nucmedbio.2021.06.006_bb0130","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.2967\/jnumed.119.226332","article-title":"A prospective observational study to evaluate the effects of long-acting somatostatin analogs on 68Ga-DOTATATE uptake in patients with neuroendocrine tumors","volume":"60","author":"G\u00e5lne","year":"2019","journal-title":"J Nucl Med"},{"issue":"30","key":"10.1016\/j.nucmedbio.2021.06.006_bb0135","article-title":"Nephrotoxicity\/renal failure after therapy with 90 Yttrium- and 177Lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors: a systematic review","volume":"30","author":"Stolniceanu","year":"2020","journal-title":"Nucl Med Commun"},{"issue":"1","key":"10.1016\/j.nucmedbio.2021.06.006_bb0140","first-page":"134","article-title":"Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy","volume":"48","author":"Konijnenberg","year":"2007","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.nucmedbio.2021.06.006_bb0145","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1118\/1.4752213","article-title":"Three-dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor radionuclide therapy","volume":"39","author":"Baechler","year":"2012","journal-title":"Med Phys"},{"issue":"3","key":"10.1016\/j.nucmedbio.2021.06.006_bb0150","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00259-013-2601-x","article-title":"Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate","volume":"41","author":"Sabet","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.nucmedbio.2021.06.006_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph10020057","article-title":"A short-term biological indicator for long-term kidney damage after radionuclide therapy in mice","volume":"10","author":"Pellegrini","year":"2017","journal-title":"Pharmaceuticals"},{"issue":"5","key":"10.1016\/j.nucmedbio.2021.06.006_bb0160","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0270-9295(03)00093-7","article-title":"Radiation nephropathy","volume":"23","author":"Cohen","year":"2003","journal-title":"Semin Nephrol"},{"issue":"2","key":"10.1016\/j.nucmedbio.2021.06.006_bb0165","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00259-006-0232-1","article-title":"Long-term toxicity of [177Lu-DOTA0,Tyr 3]octreotate in rats","volume":"34","author":"Rolleman","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.nucmedbio.2021.06.006_bb0170","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1007\/s00259-009-1282-y","article-title":"Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues","volume":"37","author":"Rolleman","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1016\/j.nucmedbio.2021.06.006_bb0175","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1681\/ASN.2004110945","article-title":"Renal tubulointerstitial changes after internal irradiation with \u03b1-particle-emitting actinium daughters","volume":"16","author":"Jaggi","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.nucmedbio.2021.06.006_bb0180","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.semnuclmed.2020.05.004","article-title":"Peptide receptor radionuclide therapy of neuroendocrine tumors","volume":"50","author":"Basu","year":"2020","journal-title":"Semin Nucl Med"},{"issue":"10","key":"10.1016\/j.nucmedbio.2021.06.006_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11864-019-0677-7","article-title":"Peptide receptor radiotherapy: current approaches and future directions","volume":"20","author":"Kong","year":"2019","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"10.1016\/j.nucmedbio.2021.06.006_bb0190","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","article-title":"Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors","volume":"42","author":"Bodei","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.nucmedbio.2021.06.006_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijrobp.2009.08.075","article-title":"The use of normal tissue complication probability (NTCP) models in the clinic","volume":"76","author":"Marks","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.nucmedbio.2021.06.006_bb0200","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.2967\/jnumed.108.053173","article-title":"MIRD pamphlet no. 20: the effect of model assumptions on kidney dosimetry and response - implications for radionuclide therapy","volume":"49","author":"Wessels","year":"2008","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.nucmedbio.2021.06.006_bb0205","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s00259-008-0778-1","article-title":"Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors","volume":"35","author":"Bodei","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.nucmedbio.2021.06.006_bb0210","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/MNM.0000000000000795","article-title":"Peptide receptor radionuclide therapy with 177 Lu-DOTA-octreotate: dosimetry, nephrotoxicity, and the effect of hematological toxicity on survival","volume":"39","author":"L\u00f6ser","year":"2018","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.nucmedbio.2021.06.006_bb0215","series-title":"Clinical applications of nuclear medicine targeted therapy","author":"Bombardieri","year":"2018"},{"issue":"3","key":"10.1016\/j.nucmedbio.2021.06.006_bb0220","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00259-018-4209-7","article-title":"Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial","volume":"46","author":"Del Prete","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.nucmedbio.2021.06.006_bb0225","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00259-015-3193-4","article-title":"Subacute haematotoxicity after PRRT with 177 Lu-DOTA-octreotate: prognostic factors, incidence and course","volume":"43","author":"Bergsma","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.nucmedbio.2021.06.006_bb0230","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2967\/jnumed.117.189712","article-title":"Persistent hematologic dysfunction after peptide receptor radionuclide therapy with 177Lu-DOTATATE: incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors","volume":"59","author":"Bergsma","year":"2018","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.nucmedbio.2021.06.006_bb0235","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00259-017-3652-1","article-title":"Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour","volume":"44","author":"Yordanova","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.nucmedbio.2021.06.006_bb0240","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s00259-018-4158-1","article-title":"Salvage peptide receptor radionuclide therapy with [177 Lu-DOTA,Tyr 3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours","volume":"46","author":"van der Zwan","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2021.06.006_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102141","article-title":"Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: a systematic review and meta-analysis","volume":"93","author":"Strosberg","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"13","key":"10.1016\/j.nucmedbio.2021.06.006_bb0250","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1007\/s00259-018-4044-x","article-title":"Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning","volume":"45","author":"Cremonesi","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.nucmedbio.2021.06.006_bb0255","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/snuc.2002.31027","article-title":"Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings","volume":"XXXII","author":"de Jong","year":"2002","journal-title":"Semin Nucl Med"},{"issue":"1 Suppl","key":"10.1016\/j.nucmedbio.2021.06.006_bb0260","first-page":"83","article-title":"Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA0,Tyr3-Octreotide and 177Lu-DOTA0,Tyr3-octreotate","volume":"46","author":"Valkema","year":"2005","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.nucmedbio.2021.06.006_bb0265","doi-asserted-by":"crossref","first-page":"306","DOI":"10.2174\/1874471011104040306","article-title":"Actinium-225 in targeted alpha-particle therapeutic applications","volume":"4","author":"Scheinberg","year":"2011","journal-title":"Curr Radiopharm"},{"issue":"11","key":"10.1016\/j.nucmedbio.2021.06.006_bb0270","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1007\/s00259-014-2857-9","article-title":"213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience","volume":"41","author":"Kratochwil","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.nucmedbio.2021.06.006_bb0275","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00259-002-0982-3","article-title":"Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine","volume":"30","author":"Rolleman","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.nucmedbio.2021.06.006_bb0280","first-page":"528","article-title":"Gelatin-based plasma expander effectively reduces renal uptake of 111in-octreotide in mice and rats","volume":"47","author":"Van Eerd","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2021.06.006_bb0285","series-title":"Practical guidance on peptide receptor radionuclide therapy (PRRNT) for neuroendocrine tumours","volume":"vol. 20","author":"IAEA Human Health Series","year":"2013"},{"issue":"3","key":"10.1016\/j.nucmedbio.2021.06.006_bb0290","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3413\/nukmed-0069","article-title":"Molecular imaging of reduced renal uptake of radiolabelled [DOTA 0,Tyr3]octreotate by the combination of lysine and Gelofusine in rats","volume":"47","author":"Rolleman","year":"2008","journal-title":"NuklearMedizin"},{"issue":"9","key":"10.1016\/j.nucmedbio.2021.06.006_bb0295","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.2967\/jnumed.108.053249","article-title":"Reducing renal uptake of radiolabeled peptides using albumin fragments","volume":"49","author":"Vegt","year":"2008","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.nucmedbio.2021.06.006_bb0300","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s00259-009-1239-1","article-title":"Albumin-derived peptides efficiently reduce renal uptake of radiolabelled peptides","volume":"37","author":"Vegt","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2021.06.006_bb0305","first-page":"1","article-title":"Renal brush border strategy: a developing procedure to reduce renal radioactivity levels of radiolabeled polypeptides","author":"Arano","year":"2020","journal-title":"Nucl Med Biol"},{"issue":"1","key":"10.1016\/j.nucmedbio.2021.06.006_bb0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13014-018-1040-z","article-title":"The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies","volume":"13","author":"van Leeuwen","year":"2018","journal-title":"Radiat Oncol"},{"issue":"14","key":"10.1016\/j.nucmedbio.2021.06.006_bb0315","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1089\/ars.2018.7517","article-title":"Protection of kidney function with human antioxidation protein \u03b1 1-microglobulin in a mouse 177 Lu-DOTATATE radiation therapy model","volume":"30","author":"Kristiansson","year":"2019","journal-title":"Antioxid Redox Signal"},{"issue":"11","key":"10.1016\/j.nucmedbio.2021.06.006_bb0320","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.2967\/jnumed.118.225243","article-title":"Recombinant A1-microglobulin is a potential kidney protector in 177Lu-octreotate treatment of neuroendocrine tumors","volume":"60","author":"Andersson","year":"2019","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.nucmedbio.2021.06.006_bb0325","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00259-006-0291-3","article-title":"Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate","volume":"34","author":"Rolleman","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.nucmedbio.2021.06.006_bb0330","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2967\/jnumed.111.098665","article-title":"Reduction of renal uptake of radiolabeled octreotate by amifostine coadministration","volume":"53","author":"Melis","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2021.06.006_bb0335","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.biopha.2017.07.091","article-title":"Renin-angiotensin-aldosterone (RAAS): the ubiquitous system for homeostasis and pathologies","volume":"94","author":"Patel","year":"2017","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"10.1016\/j.nucmedbio.2021.06.006_bb0340","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.radonc.2012.08.021","article-title":"The TGF-\u03b2 co-receptor endoglin regulates macrophage infiltration and cytokine production in the irradiated mouse kidney","volume":"105","author":"Scharpfenecker","year":"2012","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.nucmedbio.2021.06.006_bb0345","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0022-2143(99)90209-3","article-title":"Angiotensin II infusion exacerbates radiation nephropathy","volume":"134","author":"Cohen","year":"1999","journal-title":"J Lab Clin Med"},{"issue":"64","key":"10.1016\/j.nucmedbio.2021.06.006_bb0350","first-page":"1","article-title":"Nephroprotective effects of enalapril after [177Lu]-DOTATATE therapy using serial renal scintigraphies in a murine model of radiation-induced nephropathy","volume":"6","author":"Ilhan","year":"2016","journal-title":"EJNMMI Res"},{"issue":"5","key":"10.1016\/j.nucmedbio.2021.06.006_bb0355","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.ijrobp.2005.11.036","article-title":"Mitigation of radiation nephropathy after internal \u03b1-particle irradiation of kidneys","volume":"64","author":"Jaggi","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.nucmedbio.2021.06.006_bb0360","series-title":"Occupational intakes of radionuclides: part 3","first-page":"137","volume":"vol. 46","author":"ICRP","year":"2017"},{"issue":"2","key":"10.1016\/j.nucmedbio.2021.06.006_bb0365","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1021\/acs.molpharmaceut.8b01091","article-title":"Metformin reduces renal uptake of radiotracers and protects kidneys from radiation-induced damage","volume":"16","author":"Xiong","year":"2019","journal-title":"Mol Pharm"},{"issue":"12","key":"10.1016\/j.nucmedbio.2021.06.006_bb0370","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1093\/carcin\/bgy148","article-title":"Mitochondria in cancer: in the aspects of tumorigenesis and targeted therapy","volume":"39","author":"Badrinath","year":"2018","journal-title":"Carcinogenesis"},{"issue":"13","key":"10.1016\/j.nucmedbio.2021.06.006_bb0375","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.nucmedbio.2021.06.006_bb0380","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s00259-009-1216-8","article-title":"Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate","volume":"37","author":"Sandstr\u00f6m","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.nucmedbio.2021.06.006_bb0385","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2967\/jnumed.117.193706","article-title":"Dose mapping after endoradiotherapy with 177 Lu-DOTATATE\/DOTATOC by a single measurement after 4 days","volume":"59","author":"H\u00e4nscheid","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2021.06.006_bb0390","doi-asserted-by":"crossref","DOI":"10.1186\/s40658-020-00293-z","article-title":"Personalized radiation dosimetry for PRRT\u2014how many scans are really required?","volume":"7","author":"Freedman","year":"2020","journal-title":"EJNMMI Phys"},{"issue":"8","key":"10.1016\/j.nucmedbio.2021.06.006_bb0395","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0136204","article-title":"Potential biomarkers for radiation-induced renal toxicity following 177Lu-octreotate administration in mice","volume":"10","author":"Sch\u00fcler","year":"2015","journal-title":"PLoS One"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805121004881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805121004881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T04:29:45Z","timestamp":1760848185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805121004881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":79,"alternative-id":["S0969805121004881"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2021.06.006","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2021.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}